Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression
Status:
Completed
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
Depression is a common mental disorder in patients undergoing maintenance hemodialysis (MHD),
which increases the risk of cardiovascular events, hospitalization rates, and mortality, but
has not received enough attention from patients and medical staff. Sertraline is a selective
serotonin reuptake inhibitor with fewer adverse reactions and higher safety compared to other
antidepressants. This study aims to investigate the efficacy and safety of sertraline in
patients undergoing MHD with depression.
This study used a randomized controlled design and evaluated the depression status of the
patients using the Hamilton Depression Scale (HAMD). MHD patients with comorbid depression
were recruited and divided into the treatment group and the control group. The treatment
group received sertraline for antidepressant therapy, while the control group did not receive
any antidepressant medication. To investigate the efficacy and safety of sertraline before
and after intervention.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University